133 related articles for article (PubMed ID: 31209188)
1. Tiny Non-coding RNAs in Body Fluids, Possible Biomarkers for Autosomal Dominant Polycystic Kidney Disease.
Ghasemi Y; Tayebi-Khosroshahi H; Abedi B; Rahmati-Yamchi M; Alizadeh E
Iran J Kidney Dis; 2019 May; 13(3):151-164. PubMed ID: 31209188
[TBL] [Abstract][Full Text] [Related]
2. Urine microRNA as potential biomarkers of autosomal dominant polycystic kidney disease progression: description of miRNA profiles at baseline.
Ben-Dov IZ; Tan YC; Morozov P; Wilson PD; Rennert H; Blumenfeld JD; Tuschl T
PLoS One; 2014; 9(1):e86856. PubMed ID: 24489795
[TBL] [Abstract][Full Text] [Related]
3. Parallel analysis of mRNA and microRNA microarray profiles to explore functional regulatory patterns in polycystic kidney disease: using PKD/Mhm rat model.
Dweep H; Sticht C; Kharkar A; Pandey P; Gretz N
PLoS One; 2013; 8(1):e53780. PubMed ID: 23326503
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic microRNAs in polycystic kidney disease.
Yheskel M; Patel V
Curr Opin Nephrol Hypertens; 2017 Jul; 26(4):282-289. PubMed ID: 28399020
[TBL] [Abstract][Full Text] [Related]
5. Urinary MicroRNAs, Possible Biomarkers for Early Detection of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Ghasemi Y; Mardomi A; Alizadeh E; Khosroshahi HT
Iran J Kidney Dis; 2023 Mar; 1(2):73-78. PubMed ID: 37060340
[TBL] [Abstract][Full Text] [Related]
6. Exploring urinary biomarkers in autosomal dominant polycystic kidney disease.
Kawano H; Muto S; Ohmoto Y; Iwata F; Fujiki H; Mori T; Yan L; Horie S
Clin Exp Nephrol; 2015 Oct; 19(5):968-73. PubMed ID: 25543187
[TBL] [Abstract][Full Text] [Related]
7. Global analysis of urinary extracellular vesicle small RNAs in autosomal dominant polycystic kidney disease.
Ali H; Malik MZ; Abu-Farha M; Abubaker J; Cherian P; Nizam R; Jacob S; Bahbahani Y; Naim M; Ahmad S; Al-Sayegh M; Thanaraj TA; Ong ACM; Harris PC; Al-Mulla F
J Gene Med; 2024 Feb; 26(2):e3674. PubMed ID: 38404150
[TBL] [Abstract][Full Text] [Related]
8. Clinical and laboratory markers of autosomal dominant polycystic kidney disease (ADPKD) progression: an overview.
Corradi V; Gastaldon F; Virzì GM; Caprara C; Martino F; Ronco C
Minerva Med; 2015 Feb; 106(1):53-64. PubMed ID: 25300895
[TBL] [Abstract][Full Text] [Related]
9. Urine Fetuin-A is a biomarker of autosomal dominant polycystic kidney disease progression.
Piazzon N; Bernet F; Guihard L; Leonhard WN; Urfer S; Firsov D; Chehade H; Vogt B; Piergiovanni S; Peters DJ; Bonny O; Constam DB
J Transl Med; 2015 Mar; 13():103. PubMed ID: 25888842
[TBL] [Abstract][Full Text] [Related]
10. Urinary biomarkers at early ADPKD disease stage.
Petzold K; Poster D; Krauer F; Spanaus K; Andreisek G; Nguyen-Kim TD; Pavik I; Ho TA; Serra AL; Rotar L
PLoS One; 2015; 10(4):e0123555. PubMed ID: 25875363
[TBL] [Abstract][Full Text] [Related]
11. Autosomal dominant polycystic kidney disease: genetics, mutations and microRNAs.
Tan YC; Blumenfeld J; Rennert H
Biochim Biophys Acta; 2011 Oct; 1812(10):1202-12. PubMed ID: 21392578
[TBL] [Abstract][Full Text] [Related]
12. Quantification of Urinary Protein Biomarkers of Autosomal Dominant Polycystic Kidney Disease by Parallel Reaction Monitoring.
Rauniyar N; Yu X; Cantley J; Voss EZ; Belcher J; Colangelo CM; Stone KL; Dahl N; Parikh C; Lam TT; Cantley LG
Proteomics Clin Appl; 2018 Sep; 12(5):e1700157. PubMed ID: 29573172
[TBL] [Abstract][Full Text] [Related]
13. Impact of miR-192 and miR-194 on cyst enlargement through EMT in autosomal dominant polycystic kidney disease.
Kim DY; Woo YM; Lee S; Oh S; Shin Y; Shin JO; Park EY; Ko JY; Lee EJ; Bok J; Yoo KH; Park JH
FASEB J; 2019 Feb; 33(2):2870-2884. PubMed ID: 30332302
[TBL] [Abstract][Full Text] [Related]
14. Autosomal dominant polycystic kidney disease: time for a change?
Chapman AB
J Am Soc Nephrol; 2007 May; 18(5):1399-407. PubMed ID: 17429048
[TBL] [Abstract][Full Text] [Related]
15. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis.
Meijer E; Boertien WE; Nauta FL; Bakker SJ; van Oeveren W; Rook M; van der Jagt EJ; van Goor H; Peters DJ; Navis G; de Jong PE; Gansevoort RT
Am J Kidney Dis; 2010 Nov; 56(5):883-95. PubMed ID: 20888104
[TBL] [Abstract][Full Text] [Related]
16. Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study.
Kistler AD; Serra AL; Siwy J; Poster D; Krauer F; Torres VE; Mrug M; Grantham JJ; Bae KT; Bost JE; Mullen W; Wüthrich RP; Mischak H; Chapman AB
PLoS One; 2013; 8(1):e53016. PubMed ID: 23326375
[TBL] [Abstract][Full Text] [Related]
17. Safe Nanocomposite-Mediated Efficient Delivery of MicroRNA Plasmids for Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapy.
Tsai YC; Teng IL; Jiang ST; Lee YC; Chiou YY; Cheng FY
Adv Healthc Mater; 2019 Mar; 8(5):e1801358. PubMed ID: 30672150
[TBL] [Abstract][Full Text] [Related]
18. Profiling of miRNAs and target genes related to cystogenesis in ADPKD mouse models.
Woo YM; Kim DY; Koo NJ; Kim YM; Lee S; Ko JY; Shin Y; Kim BH; Mun H; Choi S; Lee EJ; Shin JO; Park EY; Bok J; Park JH
Sci Rep; 2017 Oct; 7(1):14151. PubMed ID: 29074972
[TBL] [Abstract][Full Text] [Related]
19. Parallel microarray profiling identifies ErbB4 as a determinant of cyst growth in ADPKD and a prognostic biomarker for disease progression.
Streets AJ; Magayr TA; Huang L; Vergoz L; Rossetti S; Simms RJ; Harris PC; Peters DJ; Ong AC
Am J Physiol Renal Physiol; 2017 Apr; 312(4):F577-F588. PubMed ID: 28077374
[TBL] [Abstract][Full Text] [Related]
20. Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease: A Biomarker of Disease Progression and Therapeutic Efficacy.
Alam A; Dahl NK; Lipschutz JH; Rossetti S; Smith P; Sapir D; Weinstein J; McFarlane P; Bichet DG
Am J Kidney Dis; 2015 Oct; 66(4):564-76. PubMed ID: 25960302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
